Stromal Neoplasm

cancer family

Identifier: CI-CAN-00000360
Entity page: /cancer/stromal-neoplasm ↗
Edges: 432

Neighbours: 5 genes15 drugs10 trials
Drawn: 30 of 30 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Stromal Neoplasm approved for …APPROVED_FORderived3 of 3
← approved for	Imatinibsmall molecule FDA (US) · approved · 2024-11-22 · Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).	—	approved	Malignant Gastrointestinal Stromal Tumor	1	Regulatory	openfda	graph →
← approved for	Imatinib

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

KIT Exon 11 Mutation ImatinibFDA US 2003-04-189 active / 28 trials
Curatedlevel Asensitivity· support 2civicObservedKIT altered in 77% (384 / 499 cases, largest of 3 cohorts)Regulatoryapproved for Malignant Gastrointestinal Stromal Tumor (2 approval records)context: Gastrointestinal Stromal Tumor
KIT Exon 9 Mutation ImatinibFDA US 2003-04-189 active / 28 trials
Curatedlevel Asensitivity· support 2civicObservedKIT altered in 77% (384 / 499 cases, largest of 3 cohorts)Regulatoryapproved for Malignant Gastrointestinal Stromal Tumor (2 approval records)context: Gastrointestinal Stromal Tumor
KIT Exon 11 Mutation Regorafenib Anhydrous0 active / 0 trials
Curatedlevel Bsensitivity· support 3civicObservedKIT altered in 77% (384 / 499 cases, largest of 3 cohorts)no approval record in this cancercontext: Gastrointestinal Stromal Tumor
KIT Exon 9 Mutation Sunitinib5 active / 21 trials
Curatedlevel Bsensitivity· support 2civicObservedKIT altered in 77% (384 / 499 cases, largest of 3 cohorts)no approval record in this cancercontext: Gastrointestinal Stromal Tumor
KIT Exon 9 Mutation Regorafenib Anhydrous0 active / 0 trials
Curatedlevel Bsensitivity· support 1civicObservedKIT altered in 77% (384 / 499 cases, largest of 3 cohorts)no approval record in this cancercontext: Gastrointestinal Stromal Tumor
KIT EXPRESSION ImatinibFDA US 2003-04-189 active / 28 trials
Curatedlevel Bsensitivity· support 1civicObservedKIT altered in 77% (384 / 499 cases, largest of 3 cohorts)Regulatoryapproved for Malignant Gastrointestinal Stromal Tumor (2 approval records)context: Gastrointestinal Stromal Tumor
KIT V654A Sunitinib5 active / 21 trials
Curatedlevel Bsensitivity· support 1civicObservedKIT altered in 77% (384 / 499 cases, largest of 3 cohorts)no approval record in this cancercontext: Gastrointestinal Stromal Tumor
KIT Wildtype Regorafenib Anhydrous0 active / 0 trials
Curatedlevel Bsensitivity· support 1civicObservedKIT altered in 77% (384 / 499 cases, largest of 3 cohorts)no approval record in this cancercontext: Gastrointestinal Stromal Tumor

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Stromal Neoplasm altered in cohorts of …ALTERED_INderived5 of 5
← altered in cohorts of	KIT 384 / 499 cases (77 %) · ssm · gist_msk_2022 · largest of 3 cohorts	—	—	Gastrointestinal Stromal Tumor	3	Observed	cbioportal	graph →
← altered in cohorts of	CSDE1 26 / 179 cases (15 %) · ssm · gist_msk_2025	—	—	Gastrointestinal Stromal Tumor	1	Observed	cbioportal	graph →
← altered in cohorts of	SETD2 21 / 183 cases (11 %) · ssm · gist_msk_2025	—	—	Gastrointestinal Stromal Tumor	1	Observed	cbioportal	graph →
← altered in cohorts of	TP53 20 / 183 cases (11 %) · ssm · gist_msk_2025	—	—	Gastrointestinal Stromal Tumor	1	Observed	cbioportal	graph →
← altered in cohorts of	PDGFRA 49 / 499 cases (9.8 %) · ssm · gist_msk_2022 · largest of 2 cohorts	—	—	Gastrointestinal Stromal Tumor	2	Observed	cbioportal	graph →

Stromal Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 69show all (up to 200)
→ investigated in trials for	Imatinib Mesylatesmall molecule 34 trials (3 active) · roll-up of the cancer and its descendants	—	—	Stromal Neoplasm	34	Observed	clinicaltrials	graph →
→ investigated in trials for	Imatinibsmall molecule 28 trials (9 active) · roll-up of the cancer and its descendants	—	—	Stromal Neoplasm	28	Observed	clinicaltrials	graph →
→ investigated in trials for	Sunitinibsmall molecule 21 trials (5 active) · roll-up of the cancer and its descendants	—	—	Stromal Neoplasm	21	Observed	clinicaltrials	graph →
→ investigated in trials for	Regorafenibsmall molecule 15 trials (3 active) · roll-up of the cancer and its descendants	—	—	Stromal Neoplasm	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Ripretinibsmall molecule 13 trials (4 active) · roll-up of the cancer and its descendants	—	—	Stromal Neoplasm	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Nilotinibsmall molecule 12 trials (0 active) · roll-up of the cancer and its descendants	—	—	Stromal Neoplasm	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Avapritinibsmall molecule 7 trials (0 active) · roll-up of the cancer and its descendants	—	—	Stromal Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumabmonoclonal antibody 5 trials (1 active) · roll-up of the cancer and its descendants	—	—	Stromal Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Dasatinibsmall molecule 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Stromal Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 4 trials (1 active) · roll-up of the cancer and its descendants	—	—	Stromal Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Pazopanibsmall molecule 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Stromal Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Stromal Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Binimetinibsmall molecule 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Stromal Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Pexidartinibsmall molecule 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Stromal Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Temozolomidesmall molecule 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Stromal Neoplasm	3	Observed	clinicaltrials	graph →

Stromal Neoplasm studied in …STUDIED_INderived10 of 355show all (up to 200)
→ studied in	NCT04924075Phase 2 · recruiting Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) · condition mapped CURATED_BROADER · 355 trials mapped (77 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT06441331Phase 1 · recruiting Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors · condition mapped ALIAS · 355 trials mapped (77 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT07124000recruiting DESTINY-PANTUMOUR04 · condition mapped ONTOLOGY_EXACT · 355 trials mapped (77 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT07585266Phase 3 · recruiting A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) · condition mapped ALIAS · 355 trials mapped (77 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT07837271active not recruiting Development and External Validation of a Prognostic Model for DFS After Curative Resection of Duodenal GIST · condition mapped ONTOLOGY_EXACT · 355 trials mapped (77 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT03602092completed Observational Registry Data on GIST Patients · condition mapped ONTOLOGY_EXACT · 355 trials mapped (77 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT05152472Phase 2 · recruiting A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments · condition mapped CURATED_BROADER · 355 trials mapped (77 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT00265798Phase 2 · active not recruiting Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate · condition mapped ONTOLOGY_EXACT · 355 trials mapped (77 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT05493215Phase 2 · recruiting Imatinib TDM in GIST · condition mapped ONTOLOGY_EXACT · 355 trials mapped (77 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT02402244recruiting Project: Every Child for Younger Patients With Cancer · condition mapped ONTOLOGY_EXACT · 355 trials mapped (77 active)	—	—	Stromal Neoplasm	1	Observed	clinicaltrials	graph →